Natural Capsules reported a challenging first quarter of FY27, with revenue contracting 17% year-on-year to ₹48.71 crore. Despite the top-line decline, the company managed to expand its EBITDA margin by 2 basis points to 2.30%, driven by improved realisations and timely pass-through of input cost increases. However, the net loss widened by 15% to ₹5.74 crore, compared to ₹4.96 crore in the corresponding quarter last year.

Financial Performance

The quarter’s financials reflect operational headwinds offset by margin preservation efforts and a sharp rise in non-operating income. While EBITDA fell 16% year-on-year to ₹1.12 crore, it rose 251% sequentially, indicating a recovery from the previous quarter’s low base. A significant development was the surge in other income, which jumped 556% year-on-year to ₹2.35 crore, up from ₹0.36 crore in Q1FY26. Conversely, finance costs nearly doubled, rising 97% year-on-year to ₹4.97 crore from ₹2.53 crore, exerting pressure on the bottom line.

What the Numbers Show

A significant divergence exists between operating performance and bottom-line results. While EBITDA improved sharply on a sequential basis (+251%), the net loss widened slightly (+3% QoQ). This suggests that fixed overheads, particularly the 97% year-on-year spike in finance costs, absorbed much of the operating gain. Furthermore, the 17% year-on-year revenue decline occurred alongside a 2 bps margin expansion, indicating that pricing power or mix shifts helped preserve profitability despite lower volumes. The substantial rise in other income (₹2.35 crore) partially mitigated the impact of high interest expenses on the final net loss figure.

Operational Updates

Sunil Mundra, Managing Director, noted that the reported numbers are not directly comparable to the preceding quarter, which benefited from the dispatch of deferred inventory following a plant shutdown in Puducherry. On an underlying basis, management described the performance as healthy.

Key operational developments include:

• ERP Disruption: Implementation of a new ERP system near the end of the quarter caused brief disruptions to billing and dispatch, pushing sales from the final five days into Q2. Management stated this impact modestly suppressed reported revenue.
• HPMC Segment: Due to erratic demand and duty uncertainty in the US market, the company temporarily converted one HPMC production line to gelatine capsules to optimise capacity utilisation. A second line is expected to follow next month.
• API Business: Geopolitical uncertainties and currency fluctuations (appreciating Chinese yuan, depreciating Indian rupee) weighed on African export volumes routed through merchant exporters.

Strategic Progress

Despite near-term pressures, Natural Capsules made strategic strides in its API segment. The company commenced its first batch under a contract manufacturing agreement with Fermbox Bio in August and signed a new deal with a Mumbai-based client. Technically, prednisolone synthesis was completed at gram-scale batches, with full backward-integrated production expected by September. Additionally, a fermentation step was transitioned to an enzymatic route, improving yields and cost efficiency.

Regulatory progress includes the initiation of the WHO GMP application process, with an audit expected by the end of Q2FY27. The company also appointed a Chief Operating Officer for the API business, leveraging over 30 years of industry experience.

Mundra expressed confidence in sustained performance for the capsules business through the fiscal year, citing firm demand trends into Q2FY27 and improved visibility across segments.

Natural Capsules Limited has expanded the agenda for its upcoming Board of Directors meeting on August 12, 2026, to include a significant capital-raising initiative. In addition to approving the unaudited consolidated and standalone financial results for the quarter ended June 30, 2026 (Q1FY26), the Board will evaluate a proposal to raise funds through the preferential issue of equity shares, convertibles, or other eligible securities. This move signals the company’s intent to strengthen its capital base, subject to necessary regulatory and shareholder approvals.

The company notified the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE) on August 9, 2026, regarding this addition to the agenda previously intimated on August 4, 2026. The proposed fund raising is contingent upon obtaining all required regulatory and statutory approvals, as well as explicit approval from the company’s shareholders. The specific amount to be raised or the target investors have not been disclosed in this filing.

Regulatory Compliance and Trading Window

In adherence to the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company’s internal Code of Conduct for the Prevention of Insider Trading, the trading window for dealing in the equity shares of Natural Capsules Limited remains closed. This restriction applies to all Designated Persons and their immediate relatives. The window will remain shut from July 1, 2026, until 48 hours after the declaration of the financial results for the quarter ended June 30, 2026.

Key Agenda Items

The Board meeting on August 12, 2026, focuses on two primary areas:

Akshay Dutta, Company Secretary and Compliance Officer of Natural Capsules Limited, signed the communication to the exchanges. The filing underscores the procedural steps required before any capital infusion can proceed, highlighting the need for shareholder consent alongside regulatory clearances.